InvestSMART

pSivida Limited (ASX: PSD) - Announcements

DELISTED - Current share price for PSD : $0.093

ASX company news and announcements for pSivida Limited (PSD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All pSivida Limited (PSD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than pSivida Limited (PSD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for pSivida Limited (PSD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Trading Halt 3 Aug 2005 6:14PM n/a $0.093 n/a
- Quarterly Cashflow - Commentary 29 Jul 2005 4:40PM $0.875 $0.093 fallen by 89.37%
- Commitments Test Entity - Fourth Quarter Report 29 Jul 2005 4:40PM n/a $0.093 n/a
- Chinese Patent Granted 10 May 2005 9:50AM $0.670 $0.093 fallen by 86.12%
- Expands market for lead cancer product BrachySil 8 Apr 2005 9:40AM $0.850 $0.093 fallen by 89.06%
- Production Scale-up for BrachySil Cancer Therapy 30 Mar 2005 11:43AM $0.850 $0.093 fallen by 89.06%
- Future Out-Licensing-fBioSilicon in Tissue Eng./Orthopedics 1 Mar 2005 10:30AM $0.970 $0.093 fallen by 90.41%
- Positive Phase IIa Trial Results in Liver Cancer 15 Feb 2005 9:34AM $1.130 $0.093 fallen by 91.77%
- 4th US Patent Granted 10 Jan 2005 9:57AM $1.230 $0.093 fallen by 92.44%
- Top 5 Pharma.to Evaluate BioSilicon for Drug Delivery 22 Dec 2004 12:32PM $1.260 $0.093 fallen by 92.62%
- Trading Halt 22 Dec 2004 9:33AM $1.260 $0.093 fallen by 92.62%
- New Patent Granted - BioSilicon Tablets 27 Jul 2004 9:46AM $1.120 $0.093 fallen by 91.70%
- FIRB Approval Received 8 Jul 2004 3:23PM $1.150 $0.093 fallen by 91.91%
- pSivida Acquires 100% of pSiMedica 2 Jun 2004 9:21AM $1.290 $0.093 fallen by 92.79%
- New European Patent Granted - Resorbable BioSilicon 1 Jun 2004 9:43AM $1.260 $0.093 fallen by 92.62%
- University of Pittsburgh Collaboration: DNA Vaccine Delivery 21 May 2004 9:32AM $1.120 $0.093 fallen by 91.70%
- University of Pittsburgh Collaboration: DNA Vaccine Delivery 21 May 2004 9:32AM $1.120 $0.093 fallen by 91.70%
- Second Commercial Manufacturing Agreement for BrachySil 12 May 2004 2:17PM $1.130 $0.093 fallen by 91.77%
- Second Commercial Manufacturing Agreement for BrachySil 12 May 2004 2:17PM $1.130 $0.093 fallen by 91.77%
- Final regulatory approval obtained for BrachySil Trial 27 Apr 2004 10:17AM $1.250 $0.093 fallen by 92.56%
- Final regulatory approval obtained for BrachySil Trial 27 Apr 2004 10:17AM $1.250 $0.093 fallen by 92.56%
- Additional A$6.5 M Placement to European Funds 22 Apr 2004 9:46AM $1.260 $0.093 fallen by 92.62%
- Additional A$6.5 M Placement to European Funds 22 Apr 2004 9:46AM $1.260 $0.093 fallen by 92.62%
- $21M Placement to US & European Institutions 15 Apr 2004 9:48AM $1.220 $0.093 fallen by 92.38%
- $21M Placement to US & European Institutions 15 Apr 2004 9:48AM $1.220 $0.093 fallen by 92.38%

101 - 125 of 141 results

Page 5 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.